• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Bronchiectasis: the arrival of better evidence

    Author(s)
    Goyal, V
    Grimwood, K
    Chang, AB
    Griffith University Author(s)
    Grimwood, Keith
    Year published
    2014
    Metadata
    Show full item record
    Abstract
    Bronchiectasis unrelated to cystic fibrosis is increasingly recognised as a major contributor to respiratory morbidity and mortality in children and adults living in countries of all income levels.1,2 Despite its importance, bronchiectasis has attracted little research. As a result, the management of bronchiectasis is often extrapolated from research on cystic fibrosis.1,2 However, this extrapolation might have unintended consequences. For example, recombinant human DNase, a mucolytic agent used successfully in cystic fibrosis, leads instead to increased exacerbations and hospital admissions, and accelerated pulmonary decline ...
    View more >
    Bronchiectasis unrelated to cystic fibrosis is increasingly recognised as a major contributor to respiratory morbidity and mortality in children and adults living in countries of all income levels.1,2 Despite its importance, bronchiectasis has attracted little research. As a result, the management of bronchiectasis is often extrapolated from research on cystic fibrosis.1,2 However, this extrapolation might have unintended consequences. For example, recombinant human DNase, a mucolytic agent used successfully in cystic fibrosis, leads instead to increased exacerbations and hospital admissions, and accelerated pulmonary decline in adult patients with bronchiectasis.
    View less >
    Journal Title
    The Lancet Respiratory Medicine
    Volume
    2
    Issue
    1
    DOI
    https://doi.org/10.1016/S2213-2600(13)70246-7
    Subject
    Clinical sciences
    Other health sciences
    Publication URI
    http://hdl.handle.net/10072/69077
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander